- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Rushad Patell
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 86
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Patent Foramen Ovale, Cardiac Implantable Electronic Device
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Gynecologic Cancer, Venous Thromboembolism
- Interventions
- Oral apixaban, Subcutaneous enoxaparin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Aurora, Colorado
- Conditions
- Platelet Function and Reactivity Tests
- Interventions
- Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Acetylsalicylic acid
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more
- Conditions
- Lymphoma, Acute Lymphoblastic Leukemia
- Interventions
- Apixaban, No systemic anticoagulant prophylaxis
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
- Conditions
- Atrial Fibrillation, End Stage Renal Disease
- Interventions
- apixaban, warfarin
- Drug
- Lead sponsor
- Christopher Granger, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 58
- States / cities
- Huntsville, Alabama • Fresno, California • Long Beach, California + 52 more
- Conditions
- Healthy Volunteers, Fasting, Fed
- Interventions
- Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
- Drug
- Lead sponsor
- TAHO Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,708 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Multiple Locations, Connecticut
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
- Interventions
- Apixaban
- Drug
- Lead sponsor
- James Bayley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Bariatric Surgery, Obesity
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 51
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 221
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
- Conditions
- Coagulation
- Interventions
- Whole Blood Clotting Time
- Device
- Lead sponsor
- Perosphere Technologies Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Danbury, Connecticut • Rockville, Maryland • Denville, New Jersey + 1 more
- Conditions
- Healthy Subjects
- Interventions
- Apixaban, Boost Plus
- Drug · Dietary Supplement
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation
- Interventions
- Apixaban
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Left Ventricular Thrombus
- Interventions
- Apixaban, Warfarin
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Venous Thromboembolism
- Interventions
- Apixaban 2.5 MG Oral Tablet, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 89 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Atrial Fibrillation (AF), VTE
- Interventions
- PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
- Other
- Lead sponsor
- McMaster University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Venous Thrombosis
- Interventions
- Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
- Conditions
- Venous Thrombosis
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Apixaban
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 23
- States / cities
- Aurora, Colorado • West Haven, Connecticut • Washington D.C., District of Columbia + 19 more